

SHINGRIX VACCINATION DURING THE COVID-19 PANDEMIC

We understand that during this unprecedented time, having regular wellness checkups with patients may be a challenge. Health practitioners should evaluate appropriate patients for vaccinations as they see fit.

INDICATION

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

IMPORTANT SAFETY INFORMATION

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX

Please see additional Important Safety Information for SHINGRIX on the next page and accompanying full Prescribing Information, also available at SHINGRIXHCP.com.

CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) RECOMMENDATION

In light of the COVID-19-related reduction in people accessing vaccination services, it is important to assess the vaccination status of all patients at each visit to avoid missed opportunities for vaccination and ensure timely vaccine catch-up.¹

SIDE EFFECTS OF SHINGRIX AND THE SYMPTOMS OF COVID-19

Because some symptoms of COVID-19 are similar to SHINGRIX adverse events, the following information may be helpful²:



- Make sure to tell your patients that side effects of SHINGRIX can include pain, redness, and swelling at the injection site. They may also experience muscle pain, fatigue, headache, shivering, fever, or upset stomach
- The majority of these solicited adverse reactions were mild to moderate in intensity and had a median duration of 2-3 days

The CDC has published a list of symptoms associated with COVID-19, the disease caused by infection with SARS-CoV-2³:

- Fever or chills
- Cough
- Shortness of breath or difficulty breathing
- Fatigue
- Muscle or body aches
- Headache
- New loss of taste or smell
- Sore throat
- Congestion or runny nose
- Nausea or vomiting
- Diarrhea

If you have any additional questions about potential COVID-19 symptoms, please visit the CDC's COVID-19 web page for more information.

The symptoms of COVID-19 can range in intensity from mild to severe, and they may appear 2-14 days after exposure. Please note this list does not include all possible symptoms.³



SHINGRIX
(ZOSTER VACCINE
RECOMBINANT, ADJUVANTED)

IMMUNIZATION ACTION COALITION RECOMMENDATION



“Some patients develop flu-like symptoms or fever after vaccination with SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted). Should I defer SHINGRIX vaccination because such a reaction might be confused with COVID-19?

No. If you have an opportunity to vaccinate a patient age 50 years or older who is due for Dose 1 or Dose 2 of SHINGRIX, proceed with vaccination as usual...”⁴

SHINGRIX is a 2-dose series. The second dose should be given 2–6 months after the first.²

For more information, please see the Immunization Action Coalition’s Ask the Experts COVID-19 web page.

IMPORTANT SAFETY INFORMATION (CONT’D)

- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
- Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)
- Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)
- SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see additional Important Safety Information for SHINGRIX on the previous page and accompanying full Prescribing Information, also available at [SHINGRIXHCP.com](https://www.shingrixhcp.com)

References: 1. Vaccination Guidance During a Pandemic. Centers for Disease Control and Prevention. June 9, 2020. Accessed October 14, 2020. <https://www.cdc.gov/vaccines/pandemic-guidance/index.html/importance>. 2. Prescribing Information for SHINGRIX. 3. Symptoms of Coronavirus. Centers for Disease Control and Prevention. Updated May 13, 2020. Accessed October 14, 2020. <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>. 4. COVID-19 and Routine Vaccination. Immunization Action Coalition. June 11, 2020. Accessed October 14, 2020. https://www.immunize.org/askexperts/experts_covid19.asp.



SHINGRIX
(ZOSTER VACCINE
RECOMBINANT, ADJUVANTED)

Trademarks are owned by or licensed to the GSK group of companies.



©2021 GSK or licensor.
SGXLBND210023 April 2021
Produced in USA. 0002-0011-75